Ceryvyn Therapeutics Limited

What they do

Opthea is a clinical-stage biopharmaceutical company focused on developing therapies for eye diseases. Its lead product candidate targets VEGF-C/D for retinal conditions. The company has no approved products and relies on external funding for research and development.

Revenue drivers

• No product revenue — Opthea has no approved products and generates no product revenue; operations are funded through equity issuances and a development funding agreement.
• Development Funding Agreement — A development funding agreement with investors (including Launch Therapeutics) provides funding for development activities; the agreement has been a source of capital.
• Equity financings — The company raises capital through ordinary share placements, entitlement offers, and ADS issuances on the ASX and Nasdaq.

Recent performance

For the fiscal year ended June 30, 2025, Opthea's net loss after tax was AUD 226.6 million (based on the loss per share and weighted average shares). The company reported a basic loss per share of AUD 0.3451. Net cash used in operating activities for the year was AUD 132.9 million. These results reflect ongoing research and development expenses without product revenue.

Strategy

Opthea's strategy is to advance its lead ophthalmic product candidate through clinical development. The company funds operations through equity issuances and a development funding agreement. Recent financings include a retail entitlement offer in 2024 and ADS issuances. The company is focused on regulatory and clinical milestones for its pipeline.

Risks

• Clinical development risk — Opthea's product candidates are in clinical testing and may fail to demonstrate safety or efficacy, delaying or preventing regulatory approval.
• Funding risk — The company has no product revenue and will require additional capital to fund development; it has relied on equity financings and a development funding agreement.
• Regulatory risk — Opthea must obtain regulatory approvals to commercialize its product candidates, which is uncertain and may require additional trials.
• Dependence on partners — Opthea has a development funding agreement with Launch Therapeutics and other investors; any disagreement or termination could impact development.

Outlook

Management does not provide specific revenue guidance as Opthea is a clinical-stage company. The company will continue to focus on advancing its product candidates and seeking additional financing. The development funding agreement and equity financings are expected to support operations. Future results will depend on clinical trial outcomes and regulatory developments.